Pulmonary Embolism - Pipeline Insight, 2021

Publisher Name :
Date: 12-Oct-2021
No. of pages: 60
Delivery of the Report will take 2-3 working days once order is placed.

DelveInsight's, "Pulmonary Embolism - Pipeline Insight, 2021," report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Pulmonary Embolism pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

- Global coverage

Pulmonary Embolism Understanding

Pulmonary Embolism: Overview

Pulmonary embolism (PE) describes a blockage of one of the pulmonary arteries by a blood clot that forms elsewhere in the body and travels to the lung. The symptoms of pulmonary embolism may include pleuritic chest pain, shortness of breath, rapid heart rate, and anxiety. The diagnosis of PE is most often confirmed by lung CT scan or pulmonary angiography. Treatment of pulmonary embolism is aimed at keeping the blood clot from getting bigger and preventing new clots from forming. Prompt treatment is essential to prevent serious complications or death. Anticoagulant medications, such as heparin, enoxaparin, or warfarin are usually given to help thin the blood and prevent further clotting. The major complication of anticoagulation is bleeding.

"Pulmonary Embolism - Pipeline Insight, 2021" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Pulmonary Embolism pipeline landscape is provided which includes the disease overview and Pulmonary Embolism treatment guidelines. The assessment part of the report embraces, in depth Pulmonary Embolism commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Pulmonary Embolism collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

- The companies and academics are working to assess challenges and seek opportunities that could influence Pulmonary Embolism R&D. The therapies under development are focused on novel approaches to treat/improve Pulmonary Embolism.

Pulmonary Embolism Emerging Drugs Chapters

This segment of the Pulmonary Embolism report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Pulmonary Embolism Emerging Drugs

- Recombinant staphylokinase: Supergene

Recombinant staphylokinase contains forteplase as the active substance. It is single chain molecule, consists of 138 amino acids. When staphylokinase is added to human plasma containing a fibrin clot, it preferentially reacts with plasmin at the clot surface, forming a plasmin-staphylokinase complex. The drug is in Phase III clinical evaluation for the treatment of pulmonary embolism.

- Recombinant human prourokinase: Tasly Pharmaceuticals

Recombinant human prourokinase is being developed by Tasly Pharmaceuticals, for the treatment of myocardial infarction, stroke and pulmonary embolism. Human pro-urokinase, is a single chain structure urokinase-type plasminogen activator, prepared via recombinant DNA technology. The drug is in Phase II clinical studies for the treatment of pulmonary embolism.

Further product details are provided in the report……..

Pulmonary Embolism: Therapeutic Assessment

This segment of the report provides insights about the different Pulmonary Embolism drugs segregated based on following parameters that define the scope of the report, such as:

- Major Players in Pulmonary Embolism

There are approx. 5+ key companies which are developing the therapies for Pulmonary Embolism. The companies which have their Pulmonary Embolism drug candidates in the most advanced stage, i.e. Phase III include, Supergene.

- Phases

DelveInsight's report covers around 5+ products under different phases of clinical development like

- Late stage products (Phase III)

- Mid-stage products (Phase II)

- Early-stage product (Phase I) along with the details of

- Pre-clinical and Discovery stage candidates

- Discontinued & Inactive candidates

- Route of Administration

Pulmonary Embolism pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

- Oral

- Parenteral

- Intravitreal

- Subretinal

- Topical

- Molecule Type

Products have been categorized under various Molecule types such as

- Monoclonal Antibody

- Peptides

- Polymer

- Small molecule

- Gene therapy

- Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Pulmonary Embolism: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Pulmonary Embolism therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Pulmonary Embolism drugs.

Pulmonary Embolism Report Insights

- Pulmonary Embolism Pipeline Analysis

- Therapeutic Assessment

- Unmet Needs

- Impact of Drugs

Pulmonary Embolism Report Assessment

- Pipeline Product Profiles

- Therapeutic Assessment

- Pipeline Assessment

- Inactive drugs assessment

- Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

- How many companies are developing Pulmonary Embolism drugs?

- How many Pulmonary Embolism drugs are developed by each company?

- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Pulmonary Embolism?

- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Pulmonary Embolism therapeutics?

- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

- What are the clinical studies going on for Pulmonary Embolism and their status?

- What are the key designations that have been granted to the emerging drugs?

Key Players

- Supergene

- Servier

- Daiichi Sankyo Company

- Tasly Pharmaceuticals

- Yuhan

Key Products

- Recombinant staphylokinase

- S-62798

- DS 1040

- Recombinant human prourokinase

- YHP1906

Pulmonary Embolism - Pipeline Insight, 2021

Table of Contents

Introduction
Executive Summary
Pulmonary Embolism: Overview
* Causes
* Mechanism of Action
* Signs and Symptoms
* Diagnosis
* Disease Management
Pipeline Therapeutics
* Comparative Analysis
Therapeutic Assessment
* Assessment by Product Type
* Assessment by Stage and Product Type
* Assessment by Route of Administration
* Assessment by Stage and Route of Administration
* Assessment by Molecule Type
* Assessment by Stage and Molecule Type
Pulmonary Embolism - DelveInsight's Analytical Perspective
Late Stage Products (Phase III)
* Comparative Analysis
Recombinant staphylokinase: Supergene
* Product Description
* Research and Development
* Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
* Comparative Analysis
Recombinant human prourokinase: Tasly Pharmaceuticals
* Product Description
* Research and Development
* Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
* Comparative Analysis
YHP1906: Yuhan
* Product Description
* Research and Development
* Product Development Activities
Drug profiles in the detailed report…..
Preclinical/Discovery Stage Products
* Comparative Analysis
Drug name: Company name
* Product Description
* Research and Development
* Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
* Comparative Analysis
Pulmonary Embolism Key Companies
Pulmonary Embolism Key Products
Pulmonary Embolism- Unmet Needs
Pulmonary Embolism- Market Drivers and Barriers
Pulmonary Embolism- Future Perspectives and Conclusion
Pulmonary Embolism Analyst Views
Appendix

List of Tables

Table 1 Total Products for Pulmonary Embolism
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products

List of Figures

Figure 1 Total Products for Pulmonary Embolism
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
  • Global and China Staphylococcal Infection Drugs Market Insights, Forecast to 2027
    Published: 25-Oct-2021        Price: US 3900 Onwards        Pages: 132
    Staphylococcal Infection Drugs market is segmented by region (country), players, by Type, and by Application. Players, stakeholders, and other participants in the global Staphylococcal Infection Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application in terms of revenue and forecast for the period 2016-2027. For China market, this report focuses on......
  • Global and China Equine Supplement Products Market Insights, Forecast to 2027
    Published: 25-Oct-2021        Price: US 3900 Onwards        Pages: 141
    Equine Supplement Products market is segmented by region (country), players, by Type, and by Application. Players, stakeholders, and other participants in the global Equine Supplement Products market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application in terms of revenue and forecast for the period 2016-2027. For China market, this report focuses on the Equ......
  • Global and China Postoperative Pain Therapeutics Market Insights, Forecast to 2027
    Published: 25-Oct-2021        Price: US 3900 Onwards        Pages: 147
    Postoperative Pain Therapeutics market is segmented by region (country), players, by Type, and by Application. Players, stakeholders, and other participants in the global Postoperative Pain Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application in terms of revenue and forecast for the period 2016-2027. For China market, this report focuses ......
  • Global and China Translational Regenerative Medicine Market Insights, Forecast to 2027
    Published: 25-Oct-2021        Price: US 3900 Onwards        Pages: 141
    Translational Regenerative Medicine market is segmented by region (country), players, by Type, and by Application. Players, stakeholders, and other participants in the global Translational Regenerative Medicine market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application in terms of revenue and forecast for the period 2016-2027. For China market, this report ......
  • Global and Japan Haemophilia Treatment Market Insights, Forecast to 2027
    Published: 25-Oct-2021        Price: US 3900 Onwards        Pages: 141
    Haemophilia Treatment market is segmented by region (country), players, by Type, and by Application. Players, stakeholders, and other participants in the global Haemophilia Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application in terms of revenue and forecast for the period 2016-2027. For Japan market, this report focuses on the Haemophilia T......
  • Global and China Bispecific Antibodies for Cancer Market Insights, Forecast to 2027
    Published: 25-Oct-2021        Price: US 3900 Onwards        Pages: 135
    Bispecific Antibodies for Cancer market is segmented by region (country), players, by Type, and by Application. Players, stakeholders, and other participants in the global Bispecific Antibodies for Cancer market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application in terms of revenue and forecast for the period 2016-2027. For China market, this report focuse......
  • Global and United States Embolization Microsphere Market Insights, Forecast to 2027
    Published: 25-Oct-2021        Price: US 3900 Onwards        Pages: 132
    Embolization Microsphere market is segmented by region (country), players, by Type, and by Application. Players, stakeholders, and other participants in the global Embolization Microsphere market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application in terms of revenue and forecast for the period 2016-2027. For United States market, this report focuses on the......
  • Global and Japan Antiretroviral Drug Market Size, Status and Forecast 2021-2027
    Published: 25-Oct-2021        Price: US 3900 Onwards        Pages: 97
    Global Antiretroviral Drug Scope and Market Size Antiretroviral Drug market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Antiretroviral Drug market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027. Segment by Type......
  • Global and Japan Chemotherapy Drug Market Size, Status and Forecast 2021-2027
    Published: 25-Oct-2021        Price: US 3900 Onwards        Pages: 95
    Global Chemotherapy Drug Scope and Market Size Chemotherapy Drug market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Chemotherapy Drug market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027. Segment by Type - ......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs